OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 74.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 138,025 shares of the company’s stock after purchasing an additional 58,893 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Teva Pharmaceutical Industries were worth $3,042,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Oarsman Capital Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth $29,000. Marshall & Sterling Wealth Advisors Inc. purchased a new position in Teva Pharmaceutical Industries in the fourth quarter worth about $44,000. Ameliora Wealth Management Ltd. bought a new stake in Teva Pharmaceutical Industries during the fourth quarter worth approximately $66,000. IFP Advisors Inc increased its stake in Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after acquiring an additional 1,960 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its position in Teva Pharmaceutical Industries by 27.7% during the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company’s stock valued at $96,000 after purchasing an additional 949 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 5.8%

Shares of TEVA opened at $17.92 on Tuesday. The firm has a fifty day moving average price of $15.22 and a 200-day moving average price of $17.44. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The firm has a market capitalization of $20.31 billion, a P/E ratio of -12.36, a P/E/G ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries Limited has a 12-month low of $12.47 and a 12-month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. The business had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.48 EPS. Equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on TEVA. Barclays dropped their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research note on Monday, April 28th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and increased their target price for the company from $21.00 to $23.00 in a research note on Monday. Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, May 8th. Finally, UBS Group reduced their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $24.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.